Life Biosciences launches a Phase I trial for cellular reprogramming to treat age-related macular degeneration, challenging aging norms with FDA’s Plausible Mechanism Pathway, amid rising invest...
The FDA’s updated guidelines on cellular reprogramming, highlighted by Life Biosciences’ ER-100 trial for eye conditions, signal a pivotal shift that could accelerate anti-aging therapies,...
uPAR-targeted CAR T cell therapy shows promising results in solid tumors, with recent clinical trials and FDA designations advancing cancer immunotherapy towards precision medicine. Recent advancement...
Analyzing recent rapamycin clinical trials for anti-aging, focusing on optimal dosing, safety, and the shift from off-label use to evidence-based protocols in longevity research. New human trials on r...
Recent advancements in cellular reprogramming, including significant funding and clinical trials, are transforming anti-aging science by targeting root causes of age-related diseases. Cellular reprogr...
A new AI system, DeepRare, demonstrates superior accuracy in diagnosing rare diseases using real-time data and self-reflective reasoning, as detailed in a 2026 Nature study, with potential to reduce d...
Advanced coronary CT scans with machine learning now quantify plaque volume more accurately than LDL levels, enabling early intervention and personalized prevention for cardiovascular disease. New AI-...
Life Biosciences receives FDA clearance for the first human trial of cellular reprogramming targeting glaucoma and NAION, signaling regulatory openness to longevity therapies and potential vision rest...
Stanford Medicine study finds inhibiting 15-PGDH enzyme regenerates cartilage in aged mice, offering a non-invasive osteoarthritis treatment that could reduce joint replacements and improve life quali...
Recent advances in mRNA technology for cancer vaccines show promise with improved stability, targeted delivery, and AI-driven antigen design, transforming immunotherapy approaches. Cutting-edge mRNA v...
